Pence Jacquelyn, Stockton Michelle, Bloomer Richard J
Center for Nutraceutical and Dietary Supplement Research, College of Health Sciences, University of Memphis, Memphis, TN, United States of America.
J Clin Transl Res. 2023 Apr 26;9(3):212-221. eCollection 2023 Jun 29.
Joint pain afflicts millions of adults worldwide. The effect of a bone morphogenetic protein complex on joint pain is assessed in this study.
We compared the impact of a dietary supplement protein complex (Cyplexinol) and placebo in 18 men and women (aged 43 ± 10 years) with self-reported joint pain. Subjects were randomly assigned to each condition, consumed twice daily for 14 days (900 mg/day). Subjects completed questionnaires (e.g., Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and subjective pain using a visual analog scale [VAS]) at the start and end of each treatment phase. Blood samples were analyzed for bone morphogenic protein (BMP), alkaline phosphatase, and cytokines (tumor necrosis factor [TNF]-α, interleukin [IL]-6, IL-10, IL-1β, and TGF-β). Blood was also collected on days 1 and 15 to determine the acute impact of treatment on these measures.
Pain and discomfort scores improved ( ≤ 0.05) for subjects following use of Cyplexinol but not placebo. Improvements were noted for WOMAC pain ( = 0.05), stiffness ( = 0.039), and total pain ( = 0.026), as well as VAS pain ( = 0.015), recreational activity interference ( = 0.023), mood interference ( = 0.012), and total pain ( = 0.024). A trend was noted for WOMAC physical function ( = 0.052). An approximate 50% increase in BMP5 was noted following Cyplexinol ( = 0.01), with a similar increase noted for placebo ( = 0.022). A near doubling in TGF-β ( = 0.001) was noted for Cyplexinol. No other changes of significance were noted across time, nor were any differences noted in cytokines following acute intake of the conditions ( > 0.05).
Cyplexinol can alleviate joint pain in middle-aged men and women, while elevating BMP5 and TGF-β. Cyplexinol does not influence cytokines, at least within a short 2-week supplementation period or within the 2-h post-ingestion period.
Individuals suffering with joint pain in the knee and/or hip may benefit from daily use of Cyplexinol, as we observed decreased pain and stiffness following treatment.
关节疼痛困扰着全球数百万成年人。本研究评估了一种骨形态发生蛋白复合物对关节疼痛的影响。
我们比较了一种膳食补充剂蛋白复合物(Cyplexinol)和安慰剂对18名自我报告有关节疼痛的男性和女性(年龄43±10岁)的影响。受试者被随机分配到每种情况,每天服用两次,持续14天(900毫克/天)。受试者在每个治疗阶段开始和结束时完成问卷调查(例如,西安大略和麦克马斯特大学骨关节炎指数(WOMAC)以及使用视觉模拟量表[VAS]的主观疼痛)。分析血样中的骨形态发生蛋白(BMP)、碱性磷酸酶和细胞因子(肿瘤坏死因子[TNF]-α、白细胞介素[IL]-6、IL-10、IL-1β和转化生长因子-β)。在第1天和第15天也采集血液,以确定治疗对这些指标的急性影响。
服用Cyplexinol的受试者疼痛和不适评分有所改善(≤0.05),而服用安慰剂的受试者则没有。WOMAC疼痛(=0.05)、僵硬(=0.039)和总疼痛(=0.026)以及VAS疼痛(=0.015)、娱乐活动干扰(=0.023)、情绪干扰(=0.012)和总疼痛(=0.024)均有改善。WOMAC身体功能有上升趋势(=0.052)。服用Cyplexinol后BMP5大约增加了50%(=0.01),安慰剂组也有类似增加(=0.022)。服用Cyplexinol后TGF-β几乎增加了一倍(=0.001)。随时间推移未发现其他显著变化,急性摄入这些物质后细胞因子也未发现差异(>0.05)。
Cyplexinol可以缓解中年男性和女性的关节疼痛,同时提高BMP5和TGF-β。Cyplexinol不影响细胞因子,至少在短时间的2周补充期内或摄入后2小时内不影响。
膝盖和/或臀部有关节疼痛的个体可能从每日使用Cyplexinol中受益,因为我们观察到治疗后疼痛和僵硬有所减轻。